Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study
Age and Ageing · 2024
DOI: 10.1093/ageing/afae180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, 2024. Verfasst von Francisco Tsz Tsun Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Hospitalization, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Health and Medical Research Fund Research on COVID-19, Government of the Hong Kong Special Administrative Region, Research Grants Council.
Abstract (Originalsprache)
Background
Molnupiravir and nirmatrelvir-ritonavir are orally administered pharmacotherapies for mild to moderate COVID-19. However, the effectiveness of these drugs among very old (≥80 years), hospitalised patients remains unclear, limiting the risk–benefit assessment of these antivirals in this specific group. This study investigates the effectiveness of these antivirals in reducing mortality among this group of hospitalised patients with COVID-19.
Methods
Using a territory-wide public healthcare database in Hong Kong, a target trial emulation study was conducted with data from 13 642 eligible participants for the molnupiravir trial and 9553 for the nirmatrelvir-ritonavir trial. The primary outcome was all-cause mortality. Immortal time and confounding bias was minimised using cloning-censoring-weighting approach. Mortality odds ratios were estimated by pooled logistic regression after adjusting confounding biases by stabilised inverse probability weights.
Results
Both molnupiravir (HR: 0.895, 95% CI: 0.826–0.970) and nirmatrelvir-ritonavir (HR: 0.804, 95% CI: 0.678–0.955) demonstrated moderate mortality risk reduction among oldest-old hospitalised patients. No significant interaction was observed between oral antiviral treatment and vaccination status. The 28-day risk of mortality was lower in initiators than non-initiators for both molnupiravir (risk difference: −1.09%, 95% CI: −2.29, 0.11) and nirmatrelvir-ritonavir (risk difference: −1.71%, 95% CI: −3.30, −0.16) trials. The effectiveness of these medications was observed regardless of the patients’ prior vaccination status.
Conclusions
Molnupiravir and nirmatrelvir-ritonavir are moderately effective in reducing mortality risk among hospitalised oldest-old patients with COVID-19, regardless of their vaccination status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrati…
- Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrative Region, Chi…
- Laboratory of Data Discovery for Health (D24H), 19 Science Park West Avenue, Hong Kong Science Park, Tai Po District, Hong Kong Special Administrative Region, China.
- School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrative Region, China.
- School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrative Region, China.
- Advanced Data Analytics for Medical Science (ADAMS) Limited, 19 Science Park West Avenue, Hong Kong Science Park, Tai Po District, Hong Kong Special Administrative Region, China.
ORCID-Profile: Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Ian Chi Kei Wong, Eric Yuk Fai Wan
Förderung
- Health and Medical Research Fund Research on COVID-19
- Government of the Hong Kong Special Administrative Region
- Research Grants Council
- Collaborative Research Fund
- Health Bureau
Zitieren
APA
Lai, F. T. T., Wang, B., Wei, C., Chui, C. S. L., Li, X., Cheung, C. L., Wong, I. C. K., Chan, E. W. Y., & Wan, E. Y. F. (2024). Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. Age and Ageing. https://doi.org/10.1093/ageing/afae180
Vancouver
Lai FTT, Wang B, Wei C, Chui CSL, Li X, Cheung CL, et al. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. Age and Ageing. 2024. doi:10.1093/ageing/afae180
BibTeX
@article{Lai2024,
author = {Lai, Francisco Tsz Tsun and Wang, Boyuan and Wei, Cuiling and Chui, Celine Sze Ling and Li, Xue and Cheung, Ching Lung and Wong, Ian Chi Kei and Chan, Esther Wai Yin and Wan, Eric Yuk Fai},
title = {Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study},
journal = {Age and Ageing},
year = {2024},
doi = {10.1093/ageing/afae180}
}
EUVIMED